WA
JAZZ icon

Whitebox Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Whitebox Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-15,462
Closed -$2.27M – 416
2014
Q2 		$2.27M Buy
+15,462
New +$2.14M 0.09% 206

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Whitebox Advisors's JAZZ Position: Q3 2014 in Review

Whitebox Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2014, closing a stake of 15,462 shares — an estimated $2.27M sold.

Whitebox Advisors first reported a position in JAZZ in Q2 2014 and held it in 1 quarter. The position peaked at $2.27M in Q2 2014. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2014.

  • Whitebox Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Whitebox Advisors sold 15,462 Jazz Pharmaceuticals shares in Q3 2014, an estimated $2.27M.
  • Whitebox Advisors first reported a position in Jazz Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Whitebox Advisors's Jazz Pharmaceuticals position peaked at $2.27M in Q2 2014.
  • 325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2014.

Based on Whitebox Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.